Mycofeast is a Precision Fermentation company founded in 2023 and based in Oxford, United Kingdom.
No dated funding rounds on file. This company is privately held and may be raising or operating on undisclosed capital.
No articles ingested yet for Mycofeast. Once the hourly news pipeline is live, every article the classifier tags as mentioning this company appears here with its one-line AI summary and sentiment.
Mycofeast develops fermentation-derived dairy proteins for food, beverage and health-focused products that do not rely on conventional dairy supply chains. Its October 2026 acquisition of Daisy Lab added a lactoferrin program that had reached 500-litre pilot fermentation in Auckland.
Mycofeast makes carotenoid ingredients for animal nutrition, aimed at antioxidant protection, immune function and performance in aquafeed, ruminant and other feed. On the same platform it is developing natural pigments for food and beverages as clean-label alternatives to synthetic colors.
Mycofeast screens proprietary microbial consortia across botanical bases to make fermented ingredients with targeted bioactive profiles. The platform supports ready-to-drink formulations and mix-in bases, with a library of more than 100 validated recipes for product development and scale-up.
Evolutia Bio is Mycofeast's wholly owned strain-engineering lab in San Carlos, California, formerly Willow Biosciences' Epimeron unit, which Mycofeast acquired in 2025. Its team combines conventional and transgenic strain engineering with computational biology to design production strains that link lab discovery to industrial scale-up.